266 related articles for article (PubMed ID: 30624128)
1. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
3. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
4. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
[TBL] [Abstract][Full Text] [Related]
5. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
[TBL] [Abstract][Full Text] [Related]
6. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
Int J Clin Pract; ; . PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
